Magcaldi – Bone and Muscle Health

Looking after our bones and muscles is fundamental to living a healthy, active, and independent lifestyle. We need to be mindful of what we eat, because nutrition has an imperative role in bone and muscle health. Key nutrients we need to pay special attention to include calcium, magnesium and vitamin D3. Making sure you achieve the recommended dietary intake (RDI) for these 3 nutrients throughout life will support bone strength, muscle function, and help prevent osteoporosis in later life.

Nutrients for a healthy musculoskeletal system

Calcium, magnesium and vitamin D3 are vital for bone and muscle health (Figure 1). Collectively, our bones and muscles make up the vast musculoskeletal system (Figure 2).

Figure 2: our musculoskeletal system

Its primary function is locomotion, but it also provides the framework to keep our internal organs, ligaments and nerves in the correct position. A healthy musculoskeletal system allows us to move freely, breathe, maintain our posture and perform functional tasks easily.

Different nutrient requirements throughout life

Our requirements of these 3 nutrients (calcium, magnesium and vitamin D3) changes based on age and life stage (Table 1). Therefore you need to be aware of your RDI so you can achieve it to maintain optimal bone and muscle health. You want to avoid nutritional deficiencies because it can have negative and irreversible effects on the body and overall health.

Table 1. The recommended dietary intake (RDI) of calcium, magnesium and vitamin D3 for different target groups [2].

Target group Calcium RDI (mg/day) Magnesium RDI(mg/day) Vitamin D3 RDI(µg/day)
Children 500-1,000* 80-240* 5
Adolescents 1,300 360-410* 5
Adults 1,000 310-420* 5-15*
Pregnant and breastfeeding women 1,000 310-350* 5
Menopausal women 1,300 320-420* 10-15*

*Depends on specific age or life stage

Examples of deficiency: if a child is deficient in calcium, magnesium or vitamin D3 it can stunt healthy bone growth, and may lead to a bone condition called rickets [1]. If a menopausal woman is deficient in these nutrients, her risk of osteoporosis may increase.

Groups with increased nutrient requirements

At certain points in life, your nutrient requirements (especially calcium) are heightened to support your body’s demands. Increasing your intake is important for maintaining bone strength and muscle health. This is especially important during childhood and adolescence because attaining optimal bone mass during this period is determines bone health status in later years [3].

Magcaldi® supports bone and muscle health

Magcaldi® is scientifically formulated to support bone health (i.e. density, mineralization) and healthy muscle function. It is suitable for children, adults, pregnant and breastfeeding women, menopausal women, elderly people and sports people. It features 3 key active ingredients: calcium, magnesium and vitamin D3 (Table 2).

Table 2

Nutrient Function Deficiency symptoms Source of raw material in Magcaldi®
 
  • Maintains healthy teeth and bones
  • Key structural and functional role in bones – 99% of calcium is found in bones
  • Regulates muscle (including heart) function
  • Blood clotting
  • Prolonged deficiency will cause weak and brittle bones
  • Increase risk of osteoporosis in later life
  • Risk of preterm labour and gestational hypertension in pregnant women

Calcium citrate is an absorbable form of calcium with high solubility in the body. It is absorbed equally well when taken with, or without food.

It conforms to USP 29 standard.

We source from Jiangbei Additive, a leading supplier of quality raw materials for health formulations.

 
  • Supports healthy bones – 60% of magnesium is found in bones
  • Muscle function
  • Energy production

 

  • Increased bone loss
  • Muscle spasms
  • Gastrointestinal and renal disorders
  • Increase risk of osteoporosis in later life
  • Risk of pre-eclampsia and gestational complications in pregnant women

Magnesium oxide is bioavailable source of elemental magnesium that is easily absorbed in the gut.

We source from Tomita Pharmaceutical, a leading Japanese manufacturer specialising in quality inorganic chemicals for pharmaceutical and nutraceutical industries.

  • Important for maintaining bone health (i.e. involved in calcium homeostasis)
  • Improves calcium absorption in gut
  • Severe deficiency causes softening of bones due to loss of bone mineral
  • Increase risk of osteoporosis in later life
  • Deficiency during pregnancy may also put the baby at risk of vitamin D deficiency

Quality raw material that meets the following compendia when tested: USP, Ph.Eur., and FCC.

We sourced from DSM Nutritional Products Australia, a leading supplier of vitamins for the health industry.

Quality you can trust

Magcaldi® is a complementary medicine regulated by the Therapeutic Goods Administration (TGA) – a division in the Australian Department of Health. Australia’s complementary medicine industry has one of the most stringent regulatory regimes in the world.

Magcaldi® is manufactured to a pharmaceutical standard under Good Manufacturing Practice (GMP) to meet strict safety and quality regulations. When you use Magcaldi® you can be confident that the formulation has been manufactured to high standards, and it contains the amounts stated on the label.

Clinical evidence

Calcium, magnesium and vitamin D3 supplementation has been extensively studied in different groups for its benefits on bone health (i.e. improving bone mineral density). In elderly people, improved bone minderal density also correlated to reduced risk of fractures.

Active ingredient Clinical evidence
Calcium citrate
  • In a randomized controlled trial, postmenopausal women in the treatment group received 800mg/day for 2 years (equivalent to approx. 4 Magcaldi® tablets). Results found that treatment averted bone loss and stabilized bone density [6].
  • In a prospective clinical study, postpartum women were divided in 2 groups and were given either calcium citrate 1000mg/day (equivalent to 4 Magcaldi® tablets) or a dairy product for 6 months. Results found that bone mineral density and bone mineral content were comparable in both groups [7].
  • In a randomized controlled trial, men in the treatment group were administered 1200mg/day calcium citrate (equivalent to approx. 4 Magcaldi® tablets) for 2 years. Compared to placebo, men receiving 1200mg calcium citrate reported less falls and fractures, this was attributed to higher bone mineral density [8].
Magnesium
  • In a trial consisting of athletes, magnesium supplementation was associated with improved bone mineral mass [9].
  • In a small trial, Girls (aged 8-14 years old) received oral supplementation of magnesium oxide (i.e. 300mg of elemental magnesium/day which is equivalent to approx. 4 Magcaldi® tablets). Magnesium intake was positively correlated with improved bone mineral content [10].
Vitamin D3
  • In a placebo controlled trial, elderly women in the treatment group received a daily supplement containing calcium (1.2g) and vitamin D3 (800IU) (equivalent to approx. 4 Magcaldi® tablets). Bone density was improved and the risk of hip fractures was decreased in the treatment group [11].
  • In a placebo controlled pilot study consisting of young girls (9-13 years old), the treatment group receiving calcium (800mg) and Vitamin D3 (400IU) for 6 months was associated with increased bone density and strength, compared to placebo [12].

References

  1. https://www.betterhealth.vic.gov.au/health/ConditionsAndTreatments/rickets Accessed 29/5/18
  2. https://www.nrv.gov.au/ Accessed 29/5/18
  3. https://www.bones.nih.gov/health-info/bone/bone-health/juvenile Accessed 29/5/18
  4. https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/ Accessed 1/6/18
  5. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/ Accessed 1/6/18
  6. Ruml L. A, Sakhaee, K., Peterson, R., Adams-Huet, B., Pak, C. Y. Am J Ther. 1999 Nov;6(6):303-11.
  7. Malpeli A, Apezteguia M, Mansur JL, Armanini A, Macías Couret M, Villalobos R, Kuzminczuk M, Gonzalez HF. Arch Latinoam Nutr. 2012 Mar;62(1):30-6.
  8. Reid IR, Ames R, Mason B, Reid HE, Bacon CJ, Bolland MJ, Gamble GD, Grey A, Horne A. Arch Intern Med. 2008 Nov 10;168(20):2276-82. doi: 10.1001/archinte.168.20.2276.
  9. Matias CN, Santos DA, Monteiro CP, Vasco AM, Baptista F, Sardinha LB, Laires MJ, Silva AM. Magnes Res. 2012 Jul-Sep;25(3):120-5. doi: 10.1684/mrh.2012.0317.
  10. Carpenter TO, DeLucia MC, Zhang JH, Bejnerowicz G, Tartamella L, Dziura J, Petersen KF, Befroy D, Cohen D. J Clin Endocrinol Metab. 2006 Dec;91(12):4866-72. Epub 2006 Oct 3.
  11. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ. N Engl J Med. 1992 Dec 3;327(23):1637-42.
  12. Greene DA, Naughton GA. Osteoporos Int. 2011 Feb;22(2):489-98. doi: 10.1007/s00198-010-1317-z. Epub 2010 Jun 11.
Share With:

MaxBiocare Australia